Novel GABRG2 mutations cause familial febrile seizures by Boillot, Morgane et al.
Novel GABRG2 mutations cause familial febrile seizures
Morgane Boillot, Me´lanie Morin-Brureau, Fabienne Picard, Sarah
Weckhuysen, Virginie Lambrecq, Carlo Minetti, Pasquale Striano, Federico
Zara, Michele Iacomino, Saeko Ishida, et al.
To cite this version:
Morgane Boillot, Me´lanie Morin-Brureau, Fabienne Picard, Sarah Weckhuysen, Virginie Lam-
brecq, et al.. Novel GABRG2 mutations cause familial febrile seizures. Neurology: Genetics,
2015, 1 (4), pp.e35. <10.1212/NXG.0000000000000035>. <hal-01304648>
HAL Id: hal-01304648
http://hal.upmc.fr/hal-01304648
Submitted on 20 Apr 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.





























Novel GABRG2 mutations cause familial
febrile seizures
ABSTRACT
Objective: To identify the genetic cause in a large family with febrile seizures (FS) and temporal
lobe epilepsy (TLE) and subsequently search for additional mutations in a cohort of 107 families
with FS, with or without epilepsy.
Methods: The cohort consisted of 1 large family with FS and TLE, 64 smaller French families re-
cruited through a national French campaign, and 43 Italian families. Molecular analyses consisted
of whole-exome sequencing and mutational screening.
Results: Exome sequencing revealed a p.Glu402fs*3 mutation in the g2 subunit of the GABAA
receptor gene (GABRG2) in the large family with FS and TLE. Three additional nonsense and
frameshift GABRG2 mutations (p.Arg136*, p.Val462fs*33, and p.Pro59fs*12), 1 missense
mutation (p.Met199Val), and 1 exonic deletion were subsequently identified in 5 families of the
follow-up cohort.
Conclusions: We report GABRG2 mutations in 5.6% (6/108) of families with FS, with or without
associated epilepsy. This study provides evidence that GABRG2 mutations are linked to the FS phe-
notype, rather than epilepsy, and that loss-of-function of GABAA receptor g2 subunit is the probable
underlying pathogenic mechanism. Neurol Genet 2015;1:e35; doi: 10.1212/NXG.0000000000000035
GLOSSARY
FS 5 febrile seizures; GEFS1 5 genetic epilepsy with febrile seizures plus; GTCS 5 generalized tonic-clonic seizures;
NMD 5 nonsense-mediated-decay system; TCS 5 tonic-clonic seizures; TLE 5 temporal lobe epilepsy.
Febrile seizures (FS) are the most frequent convulsive event in early infancy, affecting an estimated
2%–5% of children.1 They usually occur between 6 months and 5 years of age in the presence of
fever. The prognosis is usually good, although children who have experienced FS have a higher risk of
developing epilepsy later in life. Despite a clear genetic component, the genetics of FS is still poorly
understood.2,3 Sodium channel and GABAA receptor gene mutations have been reported in familial
syndromes including FS, such as genetic epilepsy with febrile seizures plus (GEFS1).4 Mutations in
3 ion channel genes collectively account for ;15% of GEFS1 families: SCN1B encoding the
voltage-gated sodium channel b1 subunit,5 SCN1A encoding the a1 subunit of the voltage-gated
type I sodium channel,6 and GABRG2 encoding the g2 subunit of the GABAA receptor gene.7
Mutations in the SCN1A gene are the most frequent cause of GEFS1 to date.8–10 Recently,
mutations in STX1B, encoding the presynaptic protein syntaxin-1B, were found in 6 families with
FS and epilepsy.11 We performed whole-exome sequencing in a large French family with FS and
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temporal lobe epilepsy (TLE) and identified a
pathogenic frameshift mutation in the GABRG2
gene. We subsequently identified GABRG2mu-
tations in 5 of 107 families with FS.
METHODS Patients. The French cohort consisted of 64 fam-
ilies with FS with or without epilepsy. All families were recruited
through a national French campaign on genetic studies of familial
FS conducted by Généthon in 1998–2000 (J.F. Prud’homme,
Evry, France). Inclusion criterion for this cohort was the presence
of at least 3 family members with FS (with or without associated
epilepsy) with a transmission compatible with an autosomal dom-
inant trait. Family members underwent clinical assessment using
a detailed questionnaire. Information was also obtained retrospec-
tively from medical records. Probands of all families were negative
for SCN1A and SCN1B point mutations.
The Italian cohort consisted of 43 families with at least 2 first-
degree relatives with FS, with or without epilepsy. Patient evalu-
ation included details on clinical features of seizures (semiology,
precipitating factors, duration), family and personal history of
seizures/epilepsy, and developmental milestones. All the probands
were negative for SCN1A mutations.
Standard protocol approvals, registrations, and patient
consents. Written informed consent was obtained from all par-
ticipants (or the parents of minors). The study was performed
with the approval of the Cochin-Port-Royal Hospital Ethics
Committee and the G. Gaslini Institute (No. 003771-35).
Whole-exome sequencing. Exome sequencing was performed
on genomic DNA from peripheral blood of 3 affected members
(A/II-1, A/II-4, and A/II-9) of family A. Targeted exome
sequencing, library preparation, capture (Human All exon kit
V41UTRs, 70 Mb, Agilent, Interactive Biosoftware, Rouen,
France), sequencing, and variant detection and annotation were
performed by IntegraGen (Evry, France) using a previously
described procedure.12 Variants with low quality (,20) and
low VQSLOD (logarithm of odds ratio that a variant is real vs
not under the trained gaussian mixture model) (,0) were filtered
out. Variants with a read depth .30 and allele read frequency
.0.30 were filtered. High-quality variants were further filtered
for those predicted to affect the protein-coding sequence
(nonsense, missense, frameshift, or essential splice-site) and
with a minor allele frequency (,1%) in the exome variant
server (http://evs.gs.washington.edu/EVS/).
Mutational screening of GABRG2. Follow-up screening of
GABRG2 was done by Sanger sequencing in the 43 probands
of the Italian cohort as previously described.13 Screening in the
cohort of 64 probands from French families was performed using
a targeted epilepsy gene panel (SeqCapEZ custom design, Roche
NimbleGen) including GABRG2, GABRA1, STX1B, PRRT2,
CHRNA4, CHRNA2, CHRNB2, LGI1, DEPDC5, KCNT1,
and EFHC1. Quality of raw sequencing data was assessed with
the FASTQC tool. Reads were trimmed with Trimmomatic.
BWA was used to align reads on human genome (hg19). Finally,
GATK best practices were applied to call variants. Variants with
low quality (,20) were excluded. Variants with a read depth.30
and allele read frequency .0.30 were filtered. We selected het-
erozygous nonsynonymous variants with frequency ,1% in the
exome variant server, affecting the protein-coding sequence
(nonsense, missense, frameshift, or essential splice-site) and
predicted to be damaging by at least 1 of 2 in silico prediction
tools (Sift, http://sift.jcvi.org/; PolyPhen-2, http://genetics.bwh.
harvard.edu/pph2/). We followed the guidelines for assigning
causality of sequence variants in human disease as outlined.14
Coverage of GABRG2 was satisfactory (.2503) except for exon
6, which was subsequently analyzed by traditional Sanger
sequencing. Filtered variants were validated by Sanger sequencing,
and segregation was analyzed in all available family members. Impact
of mutations was assessed with Alamut version 2.4.3 (Interactive
Biosoftware). GABRG2 mutations were mapped on the immature
peptide, according to the current convention.15,16 We compared the
frequency of rare nonsynonymous GABRG2 variants (including
missense, nonsense, essential splice-site, in-frame Indels) identified
in patients with epilepsy and those present in 33,370 European
cases from the publicly available Exome Aggregation Consortium
(ExAC) database (http://exac.broadinstitute.org) using Fisher exact
tests (accessed July 2015).
Linkage analysis. Pairwise LOD scores were calculated using
the MLINK program of the FASTLINK package version 4.1
assuming an autosomal dominant trait for FS with disease allele
frequency of 0.01 and incomplete penetrance of 85%. Because
the frequency of FS in the general population is approximately
2%–5%, we used a phenocopy rate of 3% as previously
reported.17 We considered as affected all individuals with FS.
CGH array. CGH array was performed in the 43 probands of
the Italian cohort using a custom 105K Agilent CGH array con-
taining 44K backbone genome-wide probes and approximately
60K high-density probes spanning 440 genes encoding for ion
channels (list available on request) according to previously
described protocols and bioinformatics pipelines.18
RESULTS Exome sequencing. Exome sequencing re-
vealed a pathogenic mutation in GABRG2. Clinical
features of family A were described previously.19 This
large 5-generation French family included 9 individuals
with seizures (table). All 9 patients presented simple FS
in early childhood (age at onset range: 12 months to
3 years), 7 of 9 individuals subsequently developed
focal epilepsy with EEG and clinical features strongly
suggestive of TLE, and 1 patient had only generalized
tonic-clonic seizures (GTCS). Brain MRI showed
normal hippocampal architecture and volume on both
sides in 5 patients. Interictal EEGs showed epileptiform
abnormalities localized in the temporal lobe in 6 patients,
and was normal in 1 patient (A/II-6) with FS only.
We performed whole-exome sequencing on
3 affected family members (A/II-1, A/II-4, and
A/II-9). Originally, a 20 cM spaced genome-wide
microsatellite analysis was suggestive of a locus on
chromosome 18qter and a probable second locus on
chromosome 1q25-q31 with maximum pairwise
LOD scores of 3.04 and 2.33, respectively.19 We first
focused the analysis on these 2 regions, then on the
rest of the exome dataset. According to our filtering
criteria, only 7 variants were common to all 3 siblings,
but none of the corresponding genes (ABL2,
BOD1L1, B3GALT4, EXO1, HERC4, OR5K1, or
SSH2) were functionally candidate for epilepsy or ex-
pressed in the brain. We therefore subsequently
restricted the analysis to the exome datasets of indi-
viduals A/II-1 and A/II-4, who belong to the same
branch of the family. We identified a heterozygous
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y MRI Interictal EEG
Treatment, period,
age
A/I-1 (87) p.Glu402fs*3 Yes 14 NA Focal sz (backward
deviation of head, loss
of consciousness)
6 7 NA NA NA
A/II-1 (66) p.Glu402fs*3 Yes 24 NA Focal sz (partial loss of
consciousness,
disorientation)
4 25 Normal Left temporal sharp
waves
Barbiturates,
stopped at 21 y
A/II-3 (67) p.Glu402fs*3 Yes 18 NA Focal sz (staring
glance, loss of
consciousness)




stopped at 20 y
A/II-4 (64) p.Glu402fs*3 Yes 18 6 GTCS 5 10 NA NA Barbiturates
A/II-6 (61) p.Glu402fs*3 Yes 18 5 No NA Normal None
A/II-9 (49) None Yes 12 4 GTCS, focal sz (loss of
consciousness,
gestural automatisms)





stopped at 14 y




4 30 Normal Left temporal sharp
waves
VPA, stopped at 24
y (a single sz at 30 y)




8 Ongoing Normal Left frontotemporal
spike waves
Barbiturates, VPA,
CBZ, PHT, LTG, VGB










B/II-2 (94) p.Arg136* Yes ;24 ;4 No NA NA
B/III-2 (55) NA Yes 18 4 No Normal NA
B/III-10
(67)
p.Arg136* Yes 20 4 No Normal NA
B/IV-1 (10) NA Yes 22 5 No Normal NA
B/IV-2 (42) p.Arg136* Yes 15 4.5 No Normal Normal VPA, 2–5 y
B/IV-4 (31) p.Arg136* Yes 13 5 No Normal Normal VPA, 1.5–6 y
B/IV-5 (26) None No GTCS 5 5 Normal (CT
scan)
NA None








B/V-1 (5) Unknown Yes 18 Ongoing No NA NA
C/II-1 (81) None Yes 12 3 No NA NA None
C/III-1 (52) p.Val462fs*33 Yes 14 ,2 No NA NA None
C/IV-
1 (22)
p.Val462fs*33 Yes 10 8 No NA NA VPA, 1–3 y
C/IV-2
(21)
p.Val462fs*33 Yes 13 1 No NA NA None
D/II-2 (47) p.Pro59fs*12 No TCS 17 ;35 NA NA CBZ, stopped at
;35 y
D/II-5 (52) NA No TCS, sz with confusion
and irresponsiveness
17 Ongoing NA NA PB, CBZ, LCM added
recently
D/III-1 (23) p.Pro59fs*12 Yes ;5 NA TCS, sz with
irresponsiveness
? Ongoing NA NA CBZ, switch to LCM
recently
D/III-5 (26) NA Yes NA NA No NA NA None
Continued
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deletion/insertion mutation (c.1206delinsTTCAT)
in exon 9 of the g2 subunit of the GABAA receptor
gene GABRG2 gene (located on chromosome 5) in
both A/II-1 and A/II-4. Sanger sequencing indicated
that the p.Glu402fs*3 variant was segregated within
all affected family members of the first branch, but
was not present in individual A/II-9 (figure 1). The
variant created a frameshift at codon Glu402 leading
to a new reading frame that ended in a stop codon
2 positions downstream (p.Glu402fs*3). Several ar-
guments pointed toward the pathogenicity of the
GABRG2 variant in the family: (1) the GABRG2 gene
is known to be implicated in familial epilepsies; (2)
this variant disrupts the reading frame leading to a
loss-of-function mechanism, as previously reported
for other mutations16; and (3) this truncating variant
segregated among affected family members (apart
from A/II-9). We therefore considered individual
A/II-9 as a phenocopy. We reviewed the history of
seizures of individual A/II-9, which consisted of few
episodes of FS between ages 1 and 4 years. During
adolescence, she presented a unique probable focal
seizure with loss of consciousness and gestural autom-
atisms and 2 GTCS (1 nocturnal and 1 diurnal), over
a period of 6 months (period of emotional stress). We
also noted that the mother of individual A/II-9 was
asymptomatic, as well as her sister and her children,
which confirms that this branch of the family was
unlikely to bear the same genetic defect.
Mutational screening of GABRG2 in the follow-up
cohort. Sequencing of GABRG2 was performed in a
follow-up cohort of 64 probands from French
families and 43 from Italian families with FS with
or without epilepsy (table and figure 1). CGH array
was performed in the 43 probands of the Italian
families.
Family B was a large multigenerational family,
comprising 10 affected individuals, among which 7
patients had simple FS occurring between age 13
and 24 months. All patients had normal develop-
ment. Two half brothers (B/IV-7 and B/IV-9) pre-
sented focal seizures in childhood with no history of
FS. EEG and clinical features suggested benign rolan-
dic epilepsy. Patient B/IV-5 presented at age 6 years a
single brief afebrile GTCS 2 days after a fall while
cycling with loss of consciousness of 10–15 minutes,
suggesting a possible posttraumatic event. After the
fall, her brain CT scan was normal and EEG 1 month
after the accident was normal; she received no treat-
ment. Gene panel sequencing identified a heterozy-
gous nonsense mutation (c.406C.T, p.Arg136*,
exon 4) in GABRG2 in the index case (B/III-10).
Subsequent Sanger sequencing revealed that the
p.Arg136* mutation segregated with the FS compo-
nent and was absent in the 2 individuals with focal
seizures without FS (B/IV-7 and B/IV-9) and in indi-
vidual B/IV-5 with a single GTCS and no FS.
Family C consisted of 5 affected individuals over 4
generations. Four patients (C/II-1, C/III-1, C/IV-1,
and C/IV-2) had simple FS with an age at onset
between 10 and 14 months. No information was avail-
able on the epilepsy type of the deceased patient
(C/I-1) of the first generation. FS spontaneously remit-
ted before age 3 years, except in individual C/IV-1,
whose FS lasted up to age 8 years, therefore designated
as FS1. None of the patients had subsequent epilepsy.




















y MRI Interictal EEG
Treatment, period,
age




2.5 24 NA NA VPA, switch to CBZ.
Now sz-free with
LTG
E/II-1 (56) p.Met199Val Yes 6 Childhood Absences, GTCS Childhood 25 NA NA PB, then VPA. Last
seizure at age 25 y
E/III-1 (19) p.Met199Val Yes 36 3 Absences, GTCS 3.5 11 NA NA VPA, stopped at 14
y




F/I-1 (42) Deletion Yes NA 2 No NA Normal NA None






Abbreviations: AED5 antiepileptic drug; CBZ5 carbamazepine; ESM5 ethosuximide; GTCS5 generalized tonic-clonic seizures; LCM5 lacosamide; LTG5
lamotrigine; NA 5 not available; PB 5 phenobarbital; PHT 5 phenytoin; sz 5 seizure; TCS 5 tonic-clonic seizures; VGB 5 vigabatrin; VPA 5 valproate.
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a heterozygous single base deletion (c.1382delG) in
exon 9 of GABRG2, also present in his affected sons,
but not in his father (C/II-1), which is another exam-
ple of phenocopy. DNA of his mother was not avail-
able for genetic studies to investigate the mode of
transmission of the mutation. This variant creates a
frameshift, resulting in loss of the last 6 C-terminal
amino acids and incorporation of 32 extra amino acids
with a final predicted peptide of 493 amino acids
instead of 467 (p.Val462fs*33).
Family D comprised 5 patients with FS or epi-
lepsy. Medical reports were not available for review,
but telephonic interviews with family members
revealed that 3 of them (D/III-1, D/III-5, and
D/III-7) had a history of FS, 2 of whom developed
subsequent tonic-clonic seizures (TCS) and episodes
of loss of consciousness (D/III-1 and D/III-7); 2 other
family members had TCS (D/II-2) or TCS and epi-
sodes of loss of consciousness, both without a known
history of FS (D/II-5). Insufficient information was
available to classify the epilepsy in the family as gen-
eralized or focal. A c.174_175delinsA (p.Pro59fs*12)
mutation in exon 2 of GABRG2 leading to a frame-
shift starting at codon Pro59 followed by a premature
stop codon after 12 amino acids segregated in the 3
patients whose DNA was available.
Family E comprised a father and 2 daughters with
FS, followed by early-onset absence seizures and
GTCS. Development was normal in all 3 family
members. Despite a high seizure frequency, especially
in the father, all became seizure-free with valproate. A
missense variant, c.595A.G/p.Met199Val in exon 5
of GABRG2, was found in the 3 patients. The variant
was predicted deleterious by Sift, disease-causing
by MutationTaster, and probably damaging by
PolyPhen-2. The p.Met199Val mutation is located
in the N-terminal extracellular loop of the protein
(figure 2).
An intragenic deletion in the proband of Italian
family F and his affected mother was identified
at 5q34 spanning 145K at chr5, 160.631.665–
161.067.144, and affecting coding exons 1–4 of
GABRG2. The proband (F/II-1) was an 8-year-old
boy who had recurrent episodes of simple FS between
ages 12 and 36 months, which remitted spontane-
ously. From age 5 years, he developed absence seiz-
ures and 2 GTCS, successfully treated with valproate.
His mother (F/I-1) had 4 episodes of simple FS
Figure 1 Pedigrees of the families with GABRG2 mutation segregation
Pedigrees of family A (p.Glu402fs*3), family B (p.Arg136*), family C (p.Val462fs*33), family D (p.Pro59fs*12), family E (p.Met199Val), and family F
(GABRG2 deletion) are represented. The respective GABRG2 mutations (NM_000816.3) are indicated. Individuals who carry a heterozygous GABRG2
mutation are denoted by m/1, and those negative for mutations are denoted by 1/1. Arrows indicate index cases.
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during her first 2 years of life. Both individuals had
normal cognition. No additional affected relatives
were reported.
Gene panel sequencing performed in the probands
of family B, C, D, and E did not identify other rare var-
iants in known epilepsy genes targeted in our panel.
None of the GABRG2 mutations of this study were
reported in the Exome Aggregation Consortium (Ex-
AC) database, which includes the 1000 Genomes
project database and the 6,503 exomes listed in the
exome variant server. Although we acknowledge that
the p value might be overestimated because of a
lower coverage of exons 3 and 6 in ExAC control
individuals, we observed a significant enrichment of rare
nonsynonymous GABRG2 variants in our cohort of
patients (6/108, 5.6%) compared with individuals of
European ancestry from the ExAC browser (73/33,370
(0.22%), p, 2.23 1027). To further demonstrate the
causality of the GABRG2 variants in the FS phenotype
by linkage analysis, we calculated 2-point LOD scores
in the 6 families. The sum of the maximal pairwise
LOD scores was 3.02, indicating significant likelihood
that the GABRG2 variants are causal.
Four variants (p.Glu402fs*3, p.Arg136*,
p.Val462fs*33, and p.Pro59fs*12) were securely
considered pathogenic because they introduced an
erroneous stop codon in the reading frame. While
p.Arg136* and p.Pro59fs*12 were predicted to be
degraded by the nonsense-mediated-decay system
(NMD), p.Glu402fs*3 and p.Val462fs*33, located
in the last exon of GABRG2, may escape the NMD
and lead to a truncated or a longer g2 subunit, respec-
tively. The p.Met199Val missense variant was likely
to be pathogenic according to 3 in silico prediction
tools. All mutations were novel except p.Arg136*,
which was previously reported in a family with
GEFS1, learning difficulties, and autism spectrum
disorder, although it was segregated mostly with the
FS component.20
DISCUSSION GABAA receptors mediate fast inhibi-
tory synaptic transmission in the CNS. GABAA re-
ceptors are heteropentameric ligand-gated chloride
channels combining 5 of 19 different subunits.
The most common configuration in mammals
requires 1 g2 subunit in association with 2 a1-3
and 2 b2/3 subunits.21
Up to now, mutations in the GABRG2 gene,
encoding the GABAA receptor g2 subunit, have been
reported in a subset of families, but their prevalence
remained unknown. In the literature, individuals
with GABRG2 mutations presented a variety of phe-
notypes ranging from pure FS,22 FS1 or FS and gen-
eralized epilepsy (absence seizures or GTCS),7,20,23–29
GTCS without FS,30 FS and rolandic epilepsy,31 to
possibly Dravet syndrome (a nonsense mutation was
reported in dizygotic twins with Dravet syndrome
and their healthy father).32
In this study, we assessed the frequency ofGABRG2
mutations in a large cohort of families with FS and
reported pathogenic mutations in 6/108 (5.6%) fami-
lies. First, we identified a GABRG2 disease-causing
mutation (p.Glu402fs*3) in a multiplex family with
FS and TLE, in which linkage analysis previously sug-
gested a possible digenic inheritance on 1q25-q31 and
18qter.19 However, with the finding of a clear patho-
genic mutation in GABRG2, leading to the introduc-
tion of a premature stop codon (p.Glu402fs*3), both
loci were unlikely to cause the phenotype. This study
provides a clear example of the limitation of linkage
analysis and how phenocopies can distort linkage re-
sults (1 affected member of the large family did not
carry the GABRG2 mutation). Unbiased next-
generation sequencing approaches will undoubtedly
unveil additional erroneous genetic claims in the liter-
ature. In the follow-up cohort consisting of 107 fami-
lies with FS (with or without subsequent epilepsy), we
identified 2 other frameshift mutations (p.Val462fs*33
and p.Pro59fs*12), 1 nonsense mutation (p.Arg136*),
1 missense mutation (p.Met199Val), and 1 deletion
(exons 1–4) in the GABRG2 gene. Most patients
Figure 2 Schematic representation of the g2 subunit of the GABAA receptor
with the position of all reported point mutations
Disease-causing point mutations in GABRG2 include 8 missense mutations,7,22,24,26,27,30,31
4 nonsense mutations,20,23,29,41 4 frameshifts,25 and 2 splice-sites.28,31 Mutations indicated
by a blue star were identified in this study; those indicated by a red star were previously
reported. All mutations are reported on the immature peptide. Protein structure was de-
signed according to UniProt database information (NP_000807.2).
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carrying a GABRG2mutation had a reported history of
FS (22/23), associated with TLE in 1 family (family A),
generalized epilepsy with absences and GTCS in 2
families (families E and F), and undefined epilepsy with
TCS and episodes of loss of consciousness in 1 family
(family D). GABRG2 mutations segregated predomi-
nantly with FS, indicating that GABRG2mutations are
drivers of the FS phenotype, rather than epilepsy. As
expected with common traits, several affected family
members did not carry a GABRG2 mutation: 3 family
members without a history of FS (B/IV-5, B/IV-7, and
B/IV-9) and 2 phenocopies (individuals A/II-9 and
C/II-1). Overall, the penetrance ofGABRG2mutations
was high in our cohort, with only one asymptomatic
carrier (individual A/I-2). It should be noted though
that a history of FS may have been underreported in
this generation. The relatively high frequency (5.6%)
of GABRG2mutations compared with previously pub-
lished data24,28,30 is most probably linked to the fact that
FS segregating as an autosomal dominant trait was a
study inclusion criterion. Additional genetic or epige-
netic modifiers probably determine the associated epi-
lepsy component, which can result either in no
subsequent epilepsy or in the development of both
generalized and focal seizures. Consistent with this
hypothesis, 2 Gabrg2 knock-in (p.Arg82Gln) mouse
models established in 2 different mouse strains ex-
hibited similar temperature-seizure susceptibilities,
mimicking the FS phenotype, whereas the epilepsy
phenotype was only present in 1 strain.33 This sug-
gested that FS are less sensitive to genetic background
than the associated epileptic phenotypes. An emerging
question is how to explain the link between FS and
GABAergic defects. Reports have shown that the
GEFS1-causing mutation p.Lys328Met affects the
membrane dynamics and postsynaptic aggregation
of the GABAA mutant receptor in conditions of
increased temperature, confirming the susceptibility
to temperature.6,34,35
Currently, a total of 19 different GABRG2 disease-
causing mutations have been reported (including this
study), consisting of 8 missense, 4 nonsense, 4 frame-
shifts, 2 splice-sites, and 1 deletion (figure 2). The
high rate of truncating mutations (11/19, 57%),
strengthened by this study, strongly suggests that hap-
loinsufficiency resulting in loss of function of GABAA
receptor g2 subunit underlies GABRG2-related sei-
zure phenotypes. This is concordant with numerous
in vitro functional assays showing that GABRG2
mutations resulted in mRNA degradation by
NMD, the translation of proteins retained in the
endoplasmic reticulum with impaired surface-
expression, or dysfunctional channel properties of
GABAA receptors20,25,31,32,36–38 (for review, see refer-
ences 15 and 16). However, 2 recent in vivo studies
using Gln390*-Gabrg2 knock-in mice showed that
dominant-negative effects on wild-type g2 and part-
ner subunits also certainly participated to reduce
GABA-evoked currents.33,39 A reduction in cortical
synaptic GABAergic inhibition was confirmed
to cause seizures in another p.Arg82Gln-Gabrg2
knock-in mouse model.40 Nevertheless, the link
between dysfunctional GABAA receptors and seizures
is still poorly understood.
Mutations in GABRG2 are more frequent than
initially reported, and screening of the gene should
be included when considering genetic testing in fam-
ilies with an overall mild phenotype consisting of FS
with or without epilepsy.
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